Trials.ai, Inc.

Based in the US, Trials. ai, Inc. is a software company focused on revolutionizing the clinical trial process through advanced artificial intelligence and machine learning technologies. Trials.

ai, Inc. is a software firm that specializes in transforming the clinical trial experience. Founded in 2016 in San Diego, US by Kim Walpole and Tom Walpole, the company has made strategic moves to enhance its offerings. In February 2023, Trials.

ai secured a new funding round led by Teal Ventures, raising USD 1. 30 mn, bringing the total amount raised to USD 1. 30 mn. The firm has participated in 2 deals to date.

Trials. ai offers an innovative platform designed to transform the clinical trial process through advanced artificial intelligence, specifically utilizing natural language processing (NLP) and machine learning (ML). The core product, known as the Smart Study platform, automates and digitizes the creation of study documents, thereby addressing inefficiencies inherent in traditional, manual methods. This platform mines extensive datasets from trial-related documents, including those from customers and public sources, enabling research teams to make informed decisions with greater accuracy and speed.

Trials. ai serves a diverse clientele within the life sciences sector, including pharmaceutical and biotechnology companies, facilitating the design and optimization of clinical trial protocols to enhance patient outcomes. The platform’s capabilities are applicable across various therapeutic areas, with its customer base extending to markets in North America, Europe, and Asia-Pacific. Trials.

ai generates revenue through a subscription-based model, where clients pay for access to their Smart Study platform along with its suite of AI-driven tools and algorithms. These subscriptions typically involve tiered pricing plans based on the level of service and features utilized, allowing clients to tailor their engagement according to their specific needs and scale of operations. The company's transaction structure is primarily characterized by direct business-to-business (B2B) engagements, where collaborations with life science organizations facilitate the integration of Trials. ai's technology into existing workflows.

The revenue model is reinforced by partnerships with industry stakeholders that enhance the platform's capabilities and market reach, fostering a sustainable ecosystem centered around optimizing clinical trial processes. In February 2023, ZS Associates agreed to acquire Trials. ai, Inc. from Amplify LA, Nex Cubed, Teal Ventures, and Sway Ventures, with financial terms undisclosed.

This acquisition is intended to further develop ZS Associates' clinical technology. The support from recent funding will likely be utilized to enhance product offerings and facilitate expansion into new markets.